Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Amphotericin B Liposome in Visceral Leishmaniasis
NCT03636659Phase 1Completed
- Sponsor
- Aurobindo Pharma Limited
- Start
- May 2018
- Primary completion
- Apr 2019
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of Amphotericin B liposome in visceral leishmaniasis (VL) (2 arms), sponsored by Aurobindo Pharma Limited. Primary endpoints: Maximum concentration over the steady state dosing interval at 5 days and Area under the plasma concentration time curve over the steady state dosing interval at 5 days. Started May 2018; status: completed.
02
Drugs
Amphotericin B liposome
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT03636659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636659.